C₂₂H₃₀O₄ · 358.47 g/mol
(−)-trans-Δ9-Tetrahydrocannabinolic acid A
Non-psychoactive THC precursor — neuroprotective, anti-inflammatory, antiemetic
THCA is the most abundant cannabinoid in raw, unheated cannabis — it is the direct precursor to THC. Unlike THC, THCA is non-psychoactive because its carboxyl group prevents it from fitting into CB1 receptors. When cannabis is heated (smoked, vaporized, or cooked), THCA decarboxylates to become THC. Despite being the dominant cannabinoid in fresh cannabis, THCA has received far less research attention than THC. Emerging evidence suggests THCA has neuroprotective, anti-inflammatory, and antiemetic properties through mechanisms distinct from THC.
Studies Indexed
210+
Half-Life
Converts to THC upon heating; stable in raw form at low temperatures
Primary Receptors
PPARγ (agonist), TRPM8 (antagonist), CB1/CB2 (very low affinity)
Last Updated
June 2026
THCA is synthesized in cannabis trichomes from CBGA via THCA synthase. In fresh, undried cannabis, THCA can comprise 15–25% of the plant's dry weight. The decarboxylation of THCA to THC occurs slowly at room temperature and rapidly with heat — explaining why raw cannabis does not produce intoxication when eaten. THCA's pharmacological profile is distinct from THC: it does not bind CB1 receptors with significant affinity (explaining its lack of psychoactivity) but activates PPARγ (a nuclear receptor involved in inflammation and metabolism), antagonizes TRPM8 channels (involved in cold pain and prostate cancer), and inhibits COX-1 and COX-2 enzymes. Preclinical research has identified neuroprotective effects in Parkinson's and Huntington's disease models, antiemetic properties, and anti-inflammatory activity. THCA is increasingly available in raw cannabis products and tinctures marketed for its non-psychoactive therapeutic potential.
Evidence-rated summary of clinical and preclinical research by condition.
THCA showed neuroprotective effects in mouse models of Parkinson's and Huntington's disease, reducing dopaminergic neuron loss and improving motor function via PPARγ activation. More potent than CBD in some neuroprotection models.
THCA inhibits COX-1 and COX-2 enzymes and activates PPARγ, producing anti-inflammatory effects in cell culture and animal models. May be relevant for inflammatory conditions without THC's psychoactivity.
THCA reduced nausea-induced behavior in rat models at doses lower than THC. Mechanism may involve 5-HT1A activation and PPARγ agonism. Relevant for chemotherapy-induced nausea.
THCA antagonizes TRPM8 channels, which are overexpressed in prostate cancer cells. Preclinical evidence suggests THCA may inhibit prostate cancer cell migration and invasion.
PPARγ activation by THCA may improve insulin sensitivity and reduce adipogenesis, suggesting potential for metabolic syndrome. Preclinical evidence only.
Peer-reviewed research with DOI links
Nadal X, Del Río C, Casano S, et al.
British Journal of Pharmacology
Demonstrated that THCA is a potent PPARγ agonist with neuroprotective effects in mouse models of Parkinson's and Huntington's disease, establishing PPARγ as a key mechanism for THCA's therapeutic effects.
DOI: 10.1111/bph.13771Rock EM, Parker LA
British Journal of Pharmacology
Review of THCA and CBDA anti-inflammatory mechanisms, demonstrating COX inhibition and PPARγ activation as key pathways for acidic cannabinoid anti-inflammatory activity.
DOI: 10.1111/bph.12043Known interactions with pharmaceutical drugs. Consult a healthcare provider before combining. Full interactions database →
| Drug / Class | Severity | Mechanism | Clinical Effect |
|---|---|---|---|
| NSAIDs | minor | Additive COX-1/COX-2 inhibition | Potential additive anti-inflammatory and GI effects; clinical significance unknown |
| PPARγ agonists (thiazolidinediones) | moderate | Additive PPARγ activation | Potential additive metabolic effects; monitor blood glucose |
| THC (via decarboxylation) | major | THCA converts to THC when heated | Heating THCA products produces THC and psychoactive effects — critical for dosing and legal compliance |
Critical questions that remain unanswered in the current literature — representing the frontier of THCA (Tetrahydrocannabinolic Acid) research.
Explore the clinical and preclinical evidence for THCA (Tetrahydrocannabinolic Acid) across these therapeutic areas.
